DCVC Bio closes $400 Million Fund III, AI and Automation Drive Scale for Precision Fermentation + BioAge Labs Announces IPO

Hi ,

There’s been big news across the bioeconomy this week including DCVC Bio’s close of its oversubscribed $400 million Main Fund III, Prime Medicine’s T-cell development deal with pharma giant, Bristol Myers Squibb, and the world’s first bio-concrete table lamp, now available through the biophilic lifestyle brand, NPOL.

DARPA AI BTO Pitch Day: Dec 5-6, in Washington DC

Submit your AI innovation white paper by Oct 9 for a chance at up to $300K in funding.

Submit now: https://usg.valideval.com/teams/aibto_2024/signup

*SynBioBeta is proud to be the organizing entity for DARPA’s upcoming AI BTO events.

Paul Stamets' take on SynBioBeta 2024:

A Hub for New Talent

Paul Stamets highlights SynBioBeta 2024 as the ideal place for discovering new talent and building teams. Join us in 2025 for unparalleled networking and collaboration opportunities.

Check Out Our Latest Sponsors and Exhibitors for SynBioBeta 2025!

AI and Automation Drive Bioreactor Innovations from Pharma to Precision Fermentation

The evolution of bioreactor technology, combined with AI and automation, is revolutionizing precision fermentation and scaling sustainable protein production.

DCVC Bio Closes $400 Million Fund III to Accelerate Breakthroughs in Life Sciences and Deep Tech

A promising new method for relocating proteins to their correct positions in cells offers the potential to reverse disease-related mutations.

Prime Medicine Secures $55 Million Deal with Bristol Myers Squibb to Develop Next-Gen T-Cell Therapies

Prime Medicine has partnered with Bristol Myers Squibb to develop advanced reagents for ex vivo T-cell therapies using its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology

NPOL Debuts Bio-Concrete Gathering Lamp

Designed by Normal Phenomena of Life, the Gathering Lamp utilizes bio-concrete tiles to create a unique, limited-edition lighting fixture that highlights the intersection of design and environmental responsibility.

Sekisui Chemical and LanzaTech to Build Multiple Commercial Scale Waste-to-Ethanol Facilities in Japan

The partnership aims to build multiple plants utilizing LanzaTech’s technology, with the first facility expected to produce 10 to 12 kilotons of ethanol annually.